Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Pediatric Population

Inclusion Criteria: * Boys or girls aged ≧ 1 year old to 18 years old on the day of first vaccination; * Subject and/or parents(s)/legal guardian(s) was willing to comply with planned study procedures and be available for all study visits; * Subject was in good physical health on the basis of medical history, physical examination; * Subject and/or parents(s)/legal guardian(s) must read and signed the study-specific informed consent prior to initiation of any study procedure. Exclusion Criteria: * Subject ever received influenza vaccine within the previous 6 months; * History of hypersensitivity to eggs or egg protein or similar pharmacological effects to study medication (AdimFlu-S (A/H1N1)); * Personal or family history of Guillain-Barré Syndrome; * An acute febrile illness within the last 72 hours prior to vaccination; * Subject with bleeding disorder or has any coagulation disorder that needs receipt of anticoagulants in the 3 weeks preceding inclusion contraindicating intramuscular injection; * Subjects with influenza-like illness as defined by the presence of fever (temperature ≧38.5℃ ) and at least two of the following four symptoms: headache, muscle/joint aches and pains (e.g. myalgia/arthralgia), sore throat and cough; * Female subjects who are pregnant, lactating or likely to become pregnant during the study; Women of childbearing potential disagree to use an acceptable method of contraception (e.g., hormonal contraceptives, IUD, barrier device or abstinence) throughout the study; * Treatment with an investigational drug or device, or participation in a clinical study, within 3 months before consent; * Immunodeficiency, immunosuppressive or household contact with immunosuppression; * History of wheezing or bronchodilator use within 3 months prior to study vaccine; * Receipt of live virus vaccine within 1 month prior to study vaccination or expected receipt within 2 months after first study vaccination; * Receipt of any inactivated vaccine within 2 weeks prior to study vaccination or expected receipt vaccination within 3 weeks after the immunogenicity evaluation period; * Receipt of any blood products, including immunoglobulin in the prior 3 months; * Underlying condition in the investigator's opinion may be inappropriate for vaccination; * Significant chronic illness for which inactivated influenza vaccine is recommended or commonly used.